RRM1 and plasma cell myeloma: Apaolaza, I. et al. employed the concept of genetic minimal cut sets and gene expression data to predict metabolic vulnerabilities in cancer and study the ribonucleotide reductase catalytic subunit M1 (RRM1) inhibition in myeloma cell lines.